Peritoneal fibrosis is a critical sequela that limits the application of peritoneal dialysis (PD). This study explored the role and mechanism of bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) in preventing PD-associated peritoneal injury. C57BL/6 mice were randomized into three groups: a control (saline), peritoneal injury [2.5% glucose peritoneal dialysate + lipopolysaccharide (LPS)], and peritoneal injury + exosome group. After 6 weeks, mice were dissected, and the parietal peritoneum was collected. The level of peritoneal structural and functional damage was assessed. Additionally, transcriptome analysis of the peritoneum and miRNA sequencing on BMSC-Exos were performed. The parietal peritoneum had significantly thickened, and peritoneal function was impaired in the peritoneal injury group. Peritoneal structural and functional damage was significantly reduced after exosome treatment, while peritoneal inflammation, fibrosis, angiogenesis, and mesothelial damage significantly increased. Transcriptomic analysis showed that the BMSC-Exos affected the cell cycle process, cell differentiation, and inflammatory response regulation. Significant pathways in the exosome group were enriched by inflammation, immune response, and cell differentiation, which constitute a molecular network that regulates the peritoneal protective mechanism. Additionally, inflammatory factors (TNF-α, IL-1β), fibrosis markers (α-SMA, collagen-III, fibronectin), profibrotic cytokines (TGF-β1), and angiogenesis-related factor (VEGF) were downregulated at the mRNA and protein levels through BMSC-Exos treatment. BMSC-Exos treatment can prevent peritoneal injury by inhibiting peritoneal fibrosis, inflammation, and angiogenesis, showing a multitarget regulatory effect. Therefore, BMSC-Exos therapy might be a new therapeutic strategy for treating peritoneal injury.
Get full access to this article
View all access options for this article.
References
1.
HowellM, WalkerRC, and HowardK. (2019). Cost effectiveness of dialysis modalities: a systematic review of economic evaluations. Appl Health Econ Health Policy, 17:315–330.
2.
ChoY and JohnsonDW. (2014). Peritoneal dialysis-related peritonitis: towards improving evidence, practices, and outcomes. Am J Kidney Dis, 64:278–289.
3.
JavaidMM, KhanBA, and SubramanianS. (2019). Peritoneal dialysis as initial dialysis modality: a viable option for late-presenting end-stage renal disease. J Nephrol, 32:51–56.
4.
YeatesK, ZhuN, VoneshE, TrpeskiL, BlakeP, and FentonS. (2012). Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant, 27:3568–3575.
5.
ZhouQ, BajoMA, Del PesoG, YuX, and SelgasR. (2016). Preventing peritoneal membrane fibrosis in peritoneal dialysis patients. Kidney Int, 90:515–524.
6.
ZhangZ, JiangN, and NiZ. (2017). Strategies for preventing peritoneal fibrosis in peritoneal dialysis patients: new insights based on peritoneal inflammation and angiogenesis. Front Med, 11:349–358.
7.
BajoMA, Del PesoG, and TeitelbaumI. (2017). Peritoneal membrane preservation. Semin Nephrol, 37:77–92.
8.
UenoT, NakashimaA, DoiS, KawamotoT, HondaK, YokoyamaY, DoiT, HigashiY, YoriokaN, et al. (2013). Mesenchymal stem cells ameliorate experimental peritoneal fibrosis by suppressing inflammation and inhibiting TGF-beta1 signaling. Kidney Int, 84:297–307.
9.
NagasakiK, NakashimaA, TamuraR, IshiuchiN, HondaK, UenoT, DoiS, KatoY, and MasakiT (2021). Mesenchymal stem cells cultured in serum-free medium ameliorate experimental peritoneal fibrosis. Stem Cell Res Ther, 12:203.
10.
PatelDM, ShahJ, and SrivastavaAS. (2013). Therapeutic potential of mesenchymal stem cells in regenerative medicine. Stem Cells Int, 2013:496218.
11.
ChenJS, WongVW, and GurtnerGC. (2012). Therapeutic potential of bone marrow-derived mesenchymal stem cells for cutaneous wound healing. Front Immunol, 3:192.
12.
NagaishiK, MizueY, ChikenjiT, OtaniM, NakanoM, KonariN, and FujimiyaM. (2016). Mesenchymal stem cell therapy ameliorates diabetic nephropathy via the paracrine effect of renal trophic factors including exosomes. Sci Rep, 6:34842.
13.
LiM, LiS, DuC, ZhangY, LiY, ChuL, HanX, GalonsH, ZhangY, SunH, and YuP. (2020). Exosomes from different cells: characteristics, modifications, and therapeutic applications. Eur J Med Chem, 207:112784.
14.
Murray LMA and KrasnodembskayaAD. (2019). Concise Review: intercellular communication via organelle transfer in the biology and therapeutic applications of stem cells. Stem Cells, 37:14–25.
15.
SunY, LiuG, ZhangK, CaoQ, LiuT, and LiJ. (2021). Mesenchymal stem cells-derived exosomes for drug delivery. Stem Cell Res Ther, 12:561.
16.
AlasmariWA, Abdelfattah-HassanA, El-GhazaliHM, AbdoSA, IbrahimD, ElSawyNA, El-ShetryES, SalehAA, AbourehabMAS, and MahfouzH. (2022). Exosomes derived from BM-MSCs mitigate the development of chronic kidney damage post-menopause via interfering with fibrosis and apoptosis. Biomolecules, 12:663.
17.
FanC, WangQ, ChenY, YeT, and FanY. (2022). Exosomes derived from bone mesenchymal stem cells attenuate myocardial fibrosis both in vivo and in vitro via autophagy activation: the key role of miR-199a-3p/mTOR pathway. Hum Cell, 35:817–835.
18.
MaJ, LiY, ChenM, WangW, ZhaoQ, HeB, ZhangM, and JiangY. (2022). hMSCs-derived exosome circCDK13 inhibits liver fibrosis by regulating the expression of MFGE8 through miR-17-5p/KAT2B. Cell Biol Toxicol [Epub ahead of print]; DOI: 10.1007/s10565-022-09714-4.
19.
SunC, ShiC, DuanX, ZhangY, and WangB. (2022). Exosomal microRNA-618 derived from mesenchymal stem cells attenuate the progression of hepatic fibrosis by targeting Smad4. Bioengineered, 13:5915–5927.
20.
XuL, FanY, WuL, ZhangC, ChuM, WangY, and ZhuangW. (2022). Exosomes from bone marrow mesenchymal stem cells with overexpressed Nrf2 inhibit cardiac fibrosis in rats with atrial fibrillation. Cardiovasc Ther, 2022:2687807.
21.
NiJ, McLoughlinRM, BrodovitchA, MoulinP, BrouckaertP, CasadeiB, FeronO, TopleyN, BalligandJL, and DevuystO. (2010). Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant, 25:86–96.
22.
PerteaM, PerteaGM, AntonescuCM, ChangTC, MendellJT, and SalzbergSL. (2015). StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol, 33:290–295.
23.
RobinsonMD, McCarthyDJ, and SmythGK. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 26:139–140.
24.
YokoiH, KasaharaM, MoriK, OgawaY, KuwabaraT, ImamakiH, KawanishiT, KogaK, IshiiA, et al. (2012). Pleiotrophin triggers inflammation and increased peritoneal permeability leading to peritoneal fibrosis. Kidney Int, 81:160–169.
25.
VellosoMS, OtoniA, de Paula SabinoA, de CastroWV, PintoSW, MarinhoMA, and RiosDR. (2014). Peritoneal dialysis and inflammation. Clin Chim Acta, 430:109–114.
26.
EbrahimN, AhmedIA, HussienNI, DessoukyAA, FaridAS, ElshazlyAM, MostafaO, GazzarWBE, SorourSM, et al. (2018). Mesenchymal stem cell-derived exosomes ameliorated diabetic nephropathy by autophagy induction through the mTOR signaling pathway. Cells, 7:226.
27.
NassarW, El-AnsaryM, SabryD, MostafaMA, FayadT, KotbE, TemrazM, SaadAN, EssaW, and HAdel. (2017). Erratum to: umbilical cord mesenchymal stem cells derived extracellular vesicles can safely ameliorate the progression of chronic kidney diseases. Biomater Res, 21:3.
28.
HerreraJ, HenkeCA, and BittermanPB. (2018). Extracellular matrix as a driver of progressive fibrosis. J Clin Invest, 128:45–53.
29.
ShindeAV, HumeresC, and FrangogiannisNG. (2017). The role of alpha-smooth muscle actin in fibroblast-mediated matrix contraction and remodeling. Biochim Biophys Acta Mol Basis Dis, 1863:298–309.
30.
Stachowska-PietkaJ, PoleszczukJ, FlessnerMF, LindholmB, and WaniewskiJ. (2019). Alterations of peritoneal transport characteristics in dialysis patients with ultrafiltration failure: tissue and capillary components. Nephrol Dial Transplant, 34:864–870.
31.
ShiJ, YuM, and ShengM. (2017). Angiogenesis and inflammation in peritoneal dialysis: the role of adipocytes. Kidney Blood Press Res, 42:209–219.
32.
LiPK, NgJK, and McIntyreCW. (2017). Inflammation and peritoneal dialysis. Semin Nephrol, 37:54–65.
33.
Kang DH. (2020). Loosening of the mesothelial barrier as an early therapeutic target to preserve peritoneal function in peritoneal dialysis. Kidney Res Clin Pract, 39:136–144.
34.
FergusonSW, WangJ, LeeCJ, LiuM, NeelameghamS, CantyJM, and NguyenJ. (2018). The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep, 8:1419.
35.
EirinA and LermanLO. (2021). Mesenchymal stem/stromal cell-derived extracellular vesicles for chronic kidney disease: are we there yet?. Hypertension, 78:261–269.
36.
HarrellCR, JovicicN, DjonovV, ArsenijevicN, and VolarevicV. (2019). Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. Cells, 8:1605.
37.
KadotaT, FujitaY, ArayaJ, WatanabeN, FujimotoS, KawamotoH, MinagawaS, HaraH, OhtsukaT, et al. (2021). Human bronchial epithelial cell-derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF-beta-WNT crosstalk. J Extracell Vesicles, 10:e12124.
38.
MehrotraR, DevuystO, DaviesSJ, and JohnsonDW. (2016). The current state of peritoneal dialysis. J Am Soc Nephrol, 27:3238–3252.
39.
LiaoCT, AndrewsR, WallaceLE, KhanMW, Kift-MorganA, TopleyN, FraserDJ, and TaylorPR. (2017). Peritoneal macrophage heterogeneity is associated with different peritoneal dialysis outcomes. Kidney Int, 91:1088–1103.
40.
YangCY, ChangPY, ChenJY, WuBS, YangAH, and LeeOK. (2021). Adipose-derived mesenchymal stem cells attenuate dialysis-induced peritoneal fibrosis by modulating macrophage polarization via interleukin-6. Stem Cell Res Ther, 12:193.
41.
Lo SiccoC, ReverberiD, BalbiC, UliviV, PrincipiE, PascucciL, BecheriniP, BoscoMC, VaresioL, et al. (2017). Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. Stem Cells Transl Med, 6:1018–1028.
42.
KhosrowpourZ, HashemiSM, Mohammadi-YeganehS, and SoudiS. (2017). Pretreatment of mesenchymal stem cells with leishmania major soluble antigens induce anti-inflammatory properties in mouse peritoneal macrophages. J Cell Biochem, 118:2764–2779.
43.
PadwalM, and MargettsPJ. (2016). Experimental systems to study the origin of the myofibroblast in peritoneal fibrosis. Kidney Res Clin Pract, 35:133–141.
44.
ChenYT, ChangYT, PanSY, ChouYH, ChangFC, YehPY, LiuYH, ChiangWC, ChenYM, et al. (2014). Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J Am Soc Nephrol, 25:2847–2858.
45.
VlassovAV, MagdalenoS, SetterquistR, and ConradR. (2012). Exosomes: current knowledge of their composition, biological functions, and diagnostic and therapeutic potentials. Biochim Biophys Acta, 1820:940–948.
46.
QuY, ZhangQ, CaiX, LiF, MaZ, XuM, and LuL. (2017). Exosomes derived from miR-181-5p-modified adipose-derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J Cell Mol Med, 21:2491–2502.
47.
LiQ, JinY, YeX, WangW, DengG, and ZhangX. (2021). Bone marrow mesenchymal stem cell-derived exosomal MicroRNA-133a restrains myocardial fibrosis and epithelial-mesenchymal transition in viral myocarditis rats through suppressing MAML1. Nanoscale Res Lett, 16:111.
48.
YuZ, WenY, JiangN, LiZ, GuanJ, ZhangY, DengC, ZhaoL, ZhengSG, et al. (2022). TNF-alpha stimulation enhances the neuroprotective effects of gingival MSCs derived exosomes in retinal ischemia-reperfusion injury via the MEG3/miR-21a-5p axis. Biomaterials, 284:121484.
49.
LiuY, ZhangZ, WangB, DongY, ZhaoC, ZhaoY, ZhangL, LiuX, GuoJ, et al. (2022). Inflammation-stimulated MSC-derived small extracellular vesicle miR-27b-3p regulates macrophages by targeting CSF-1 to promote temporomandibular joint condylar regeneration. Small, 18:e2107354.
50.
LiuJH, LiC, CaoL, ZhangCH, and ZhangZH. (2021). Exosomal miR-132-3p from mesenchymal stem cells alleviated LPS-induced acute lung injury by repressing TRAF6. Autoimmunity, 54:493–503.
51.
FangSB, ZhangHY, WangC, HeBX, LiuXQ, MengXC, PengYQ, XuZB, FanXL, et al. (2020). Small extracellular vesicles derived from human mesenchymal stromal cells prevent group 2 innate lymphoid cell-dominant allergic airway inflammation through delivery of miR-146a-5p. J Extracell Vesicles, 9:1723260.
52.
LuFB, ChenDZ, ChenL, HuED, WuJL, LiH, GongYW, LinZ, WangXD, et al. (2019). Attenuation of experimental autoimmune hepatitis in mice with bone mesenchymal stem cell-derived exosomes carrying MicroRNA-223-3p. Mol Cells, 42:906–918.
53.
QiuM, LiuD, and FuQ. (2021). MiR-129-5p shuttled by human synovial mesenchymal stem cell-derived exosomes relieves IL-1beta induced osteoarthritis via targeting HMGB1. Life Sci, 269:118987.
54.
ZhengY, LiuJ, ChenP, LinL, LuoY, MaX, LinJ, ShenY, and ZhangL. (2021). Exosomal miR-22-3p from human umbilical cord blood-derived mesenchymal stem cells protects against lipopolysaccharid-induced acute lung injury. Life Sci, 269:119004.
55.
ZhaoY, GanY, XuG, HuaK, and LiuD. (2020). Exosomes from MSCs overexpressing microRNA-223-3p attenuate cerebral ischemia through inhibiting microglial M1 polarization mediated inflammation. Life Sci, 260:118403.
56.
CaiG, CaiG, ZhouH, ZhuangZ, LiuK, PeiS, WangY, WangH, WangX, et al. (2021). Mesenchymal stem cell-derived exosome miR-542-3p suppresses inflammation and prevents cerebral infarction. Stem Cell Res Ther, 12:2.
57.
WangY, LaiX, WuD, LiuB, WangN, and RongL. (2021). Umbilical mesenchymal stem cell-derived exosomes facilitate spinal cord functional recovery through the miR-199a-3p/145-5p-mediated NGF/TrkA signaling pathway in rats. Stem Cell Res Ther, 12:117.
58.
PengY, ZhaoJL, PengZY, XuWF, and YuGL. (2020). Exosomal miR-25-3p from mesenchymal stem cells alleviates myocardial infarction by targeting pro-apoptotic proteins and EZH2. Cell Death Dis, 11:317.
59.
JinZ, RenJ, and QiS. (2020). Exosomal miR-9-5p secreted by bone marrow-derived mesenchymal stem cells alleviates osteoarthritis by inhibiting syndecan-1. Cell Tissue Res, 381:99–114.
60.
HuX, ShenN, LiuA, WangW, ZhangL, SuiZ, TangQ, DuX, YangN, et al. (2022). Bone marrow mesenchymal stem cell-derived exosomal miR-34c-5p ameliorates RIF by inhibiting the core fucosylation of multiple proteins. Mol Ther, 30:763–781.
61.
LiY, ShenZ, JiangX, WangY, YangZ, MaoY, WuZ, LiG, and ChenH. (2022). Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3beta pathway via c-MET in radiation-induced lung injury. J Exp Clin Cancer Res, 41:128.
62.
BaralH, UchiyamaA, YokoyamaY, SekiguchiA, YamazakiS, AmaliaSN, InoueY, OginoS, ToriiR, et al. (2021). Antifibrotic effects and mechanisms of mesenchymal stem cell-derived exosomes in a systemic sclerosis mouse model: possible contribution of miR-196b-5p. J Dermatol Sci, 104:39–47.
63.
YanF, CuiW, and ChenZ. (2022). Mesenchymal stem cell-derived exosome-loaded microRNA-129-5p Inhibits TRAF3 expression to alleviate apoptosis and oxidative stress in heart failure. Cardiovasc Toxicol, 22:631–645.
64.
ZhengJ, ZhangX, CaiW, YangY, GuoT, LiJ, and DaiH. (2022). Bone marrow mesenchymal stem cell-derived exosomal microRNA-29b-3p promotes angiogenesis and ventricular remodeling in rats with myocardial infarction by targeting ADAMTS16. Cardiovasc Toxicol, 22:689–700.
65.
ZhangY, PanY, LiuY, LiX, TangL, DuanM, LiJ, and ZhangG. (2021). Exosomes derived from human umbilical cord blood mesenchymal stem cells stimulate regenerative wound healing via transforming growth factor-beta receptor inhibition. Stem Cell Res Ther, 12:434.
66.
WuL, RongC, ZhouQ, ZhaoX, ZhuansunXM, WanS, SunMM, and WangSL. (2020). Bone marrow mesenchymal stem cells ameliorate cisplatin-induced renal fibrosis via miR-146a-5p/Tfdp2 axis in renal tubular epithelial cells. Front Immunol, 11:623693.
67.
WangC, GuS, CaoH, LiZ, XiangZ, HuK, and HanX. (2016). miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis. Sci Rep, 6:30122.
68.
CuiH, BanerjeeS, XieN, GeJ, LiuRM, MatalonS, ThannickalVJ, and LiuG. (2016). MicroRNA-27a-3p Is a Negative Regulator of Lung Fibrosis by Targeting Myofibroblast Differentiation. Am J Respir Cell Mol Biol, 54:843–852.
69.
LiuY, DingY, HouY, YuT, NieH, and CuiY. (2021). The miR-130a-3p/TGF-betaRII axis participates in inhibiting the differentiation of fibroblasts induced by TGF-beta1. Front Pharmacol, 12:732540.
DuZ, WuT, LiuL, LuoB, and WeiC. (2021). Extracellular vesicles-derived miR-150-5p secreted by adipose-derived mesenchymal stem cells inhibits CXCL1 expression to attenuate hepatic fibrosis. J Cell Mol Med, 25:701–715.
72.
XiaoK, HeW, GuanW, HouF, YanP, XuJ, ZhouT, LiuY, and XieL. (2020). Mesenchymal stem cells reverse EMT process through blocking the activation of NF-kappaB and Hedgehog pathways in LPS-induced acute lung injury. Cell Death Dis, 11:863.
73.
ZhuW, SunL, ZhaoP, LiuY, ZhangJ, ZhangY, HongY, ZhuY, LuY, et al. (2021). Macrophage migration inhibitory factor facilitates the therapeutic efficacy of mesenchymal stem cells derived exosomes in acute myocardial infarction through upregulating miR-133a-3p. J Nanobiotechnol, 19:61.
74.
YuM, LiuW, LiJ, LuJ, LuH, JiaW, and LiuF. (2020). Exosomes derived from atorvastatin-pretreated MSC accelerate diabetic wound repair by enhancing angiogenesis via AKT/eNOS pathway. Stem Cell Res Ther, 11:350.
75.
YangK, LiD, WangM, XuZ, ChenX, LiuQ, SunW, LiJ, GongY, et al. (2019). Exposure to blue light stimulates the proangiogenic capability of exosomes derived from human umbilical cord mesenchymal stem cells. Stem Cell Res Ther, 10:358.
76.
ChenZ, WangH, XiaY, YanF, and LuY. (2018). Therapeutic Potential of Mesenchymal Cell-Derived miRNA-150-5p-Expressing Exosomes in Rheumatoid Arthritis Mediated by the Modulation of MMP14 and VEGF. J Immunol, 201:2472–2482.
77.
NingW, LiS, YangW, YangB, XinC, PingX, HuangC, GuY, and GuoL. (2021). Blocking exosomal miRNA-153-3p derived from bone marrow mesenchymal stem cells ameliorates hypoxia-induced myocardial and microvascular damage by targeting the ANGPT1-mediated VEGF/PI3k/Akt/eNOS pathway. Cell Signal, 77:109812.
78.
YueXH, GuoL, WangZY, and JiaTH. (2019). Inhibition of miR-17-5p promotes mesenchymal stem cells to repair spinal cord injury. Eur Rev Med Pharmacol Sci, 23:3899–3907.
79.
PanJ, LuoX, ZhaoS, LiJ, and JiangZ. (2022). miR-340-5p mediates the therapeutic effect of mesenchymal stem cells on corneal neovascularization. Graefes Arch Clin Exp Ophthalmol, 260:497–507.
80.
GaoF, SunM, GongY, WangH, WangY, and HouH. (2016). MicroRNA-195a-3p inhibits angiogenesis by targeting Mmp2 in murine mesenchymal stem cells. Mol Reprod Dev, 83:413–423.
81.
DavisC, DukesA, DrewryM, HelwaI, JohnsonMH, IsalesCM, HillWD, LiuY, ShiX, FulzeleS, and HamrickMW. (2017). MicroRNA-183-5p Increases with Age in bone-derived extracellular vesicles, suppresses bone marrow stromal (Stem) cell proliferation, and induces stem cell senescence. Tissue Eng Part A, 23:1231–1240.
82.
FengW, JinQ, Ming-YuY, YangH, XuT, You-XingS, Xu-TingB, WanC, Yun-JiaoW, et al. (2021). MiR-6924-5p-rich exosomes derived from genetically modified Scleraxis-overexpressing PDGFRalpha(+) BMMSCs as novel nanotherapeutics for treating osteolysis during tendon-bone healing and improving healing strength. Biomaterials, 279:121242.
83.
GaoS, YangD, HuangW, WangT, and LiW. (2018). miR-135a-5p affects adipogenic differentiation of human adipose-derived mesenchymal stem cells by promoting the Hippo signaling pathway. Int J Clin Exp Pathol, 11:1347–1355.
84.
YaoX, MaoY, WuD, ZhuY, LuJ, HuangY, GuoY, WangZ, ZhuS, LiX, and LuY. (2021). Exosomal circ_0030167 derived from BM-MSCs inhibits the invasion, migration, proliferation and stemness of pancreatic cancer cells by sponging miR-338-5p and targeting the Wif1/Wnt8/beta-catenin axis. Cancer Lett, 512:38–50.
85.
ZhangX, ZhuY, ZhangC, LiuJ, SunT, LiD, NaQ, XianCJ, WangL, and TengZ. (2018). miR-542-3p prevents ovariectomy-induced osteoporosis in rats via targeting SFRP1. J Cell Physiol, 233:6798–6806.
86.
BorkS, HornP, CastoldiM, HellwigI, HoAD, and WagnerW. (2011). Adipogenic differentiation of human mesenchymal stromal cells is down-regulated by microRNA-369-5p and up-regulated by microRNA-371. J Cell Physiol, 226:2226–2234.
87.
YangC, LuoM, ChenY, YouM, and ChenQ. (2021). MicroRNAs as important regulators mediate the multiple differentiation of mesenchymal stromal cells. Front Cell Dev Biol, 9:619842.
88.
MaoG, ZhangZ, HuS, ZhangZ, ChangZ, HuangZ, LiaoW, and KangY. (2018). Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A. Stem Cell Res Ther, 9:247.
89.
LinX, WuL, ZhangZ, YangR, GuanQ, HouX, and WuQ. (2014). MiR-335-5p promotes chondrogenesis in mouse mesenchymal stem cells and is regulated through two positive feedback loops. J Bone Miner Res, 29:1575–1585.
90.
ZhaoC, GuY, WangY, QinQ, WangT, HuangM, ZhangH, QuY, ZhangJ, et al. (2021). miR-129-5p Promotes Osteogenic Differentiation of BMSCs and Bone Regeneration via Repressing Dkk3. Stem Cells Int, 2021:7435605.
91.
CostaV, RaimondiL, ConigliaroA, SalamannaF, CarinaV, De LucaA, BellaviaD, AlessandroR, FiniM, and GiavaresiG. (2017). Hypoxia-inducible factor 1Alpha may regulate the commitment of mesenchymal stromal cells toward angio-osteogenesis by mirna-675-5P. Cytotherapy, 19:1412–1425.
92.
LongC, CenS, ZhongZ, ZhouC, and ZhongG. (2021). FOXO3 is targeted by miR-223-3p and promotes osteogenic differentiation of bone marrow mesenchymal stem cells by enhancing autophagy. Hum Cell, 34:14–27.
93.
ZhangM, YuanSZ, SunH, SunL, ZhouD, and YanJ. (2020). miR-199b-5p promoted chondrogenic differentiation of C3H10T1/2 cells by regulating JAG1. J Tissue Eng Regen Med, 14:1618–1629.
94.
HwangS, ParkSK, LeeHY, KimSW, LeeJS, ChoiEK, YouD, KimCS, and SuhN. (2014). miR-140-5p suppresses BMP2-mediated osteogenesis in undifferentiated human mesenchymal stem cells. FEBS Lett, 588:2957–2963.
95.
ChenN, YangH, SongL, LiH, LiuY, and WuD. (2021). MicroRNA-409-3p promotes osteoblastic differentiation via activation of Wnt/beta-catenin signaling pathway by targeting SCAI. Biosci Rep, 41:BSR20201902.
ChenG, HuangG, LinH, WuX, TanX, and ChenZ. (2021). MicroRNA-425-5p modulates osteoporosis by targeting annexin A2. Immun Ageing, 18:45.
102.
JiangH, KitauraH, LiuL, MizoguchiI, and LiuS. (2021). The miR-155-5p inhibits osteoclast differentiation through targeting CXCR2 in orthodontic root resorption. J Periodontal Res, 56:761–773.
103.
FengH, GeF, DuL, ZhangZ, and LiuD. (2019). MiR-34b-3p represses cell proliferation, cell cycle progression and cell apoptosis in non-small-cell lung cancer (NSCLC) by targeting CDK4. J Cell Mol Med, 23:5282–5291.
104.
FanY, LiY, ZhuY, DaiG, WuD, GaoZ, ZhangL, and XuD. (2021). miR-301b-3p regulates breast cancer cell proliferation, migration, and invasion by targeting NR3C2. J Oncol, 2021:8810517.
105.
HuangY, ChenL, ChenD, FanP, and YuH. (2022). Exosomal microRNA-140-3p from human umbilical cord mesenchymal stem cells attenuates joint injury of rats with rheumatoid arthritis by silencing SGK1. Mol Med, 28:36.
LiW, JinLY, CuiYB, and XieN. (2021). Human umbilical cord mesenchymal stem cells-derived exosomal microRNA-17-3p ameliorates inflammatory reaction and antioxidant injury of mice with diabetic retinopathy via targeting STAT1. Int Immunopharmacol, 90:107010.
108.
ZhangL, WeiQ, LiuX, ZhangT, WangS, ZhouL, ZouL, FanF, ChiH, SunJ, and WangD. (2021). Exosomal microRNA-98-5p from hypoxic bone marrow mesenchymal stem cells inhibits myocardial ischemia-reperfusion injury by reducing TLR4 and activating the PI3K/Akt signaling pathway. Int Immunopharmacol, 101:107592.
109.
LiangG, QinZ, LuoY, YinJ, ShiZ, WeiR, and MaW. (2022). Exosomal microRNA-133b-3p from bone marrow mesenchymal stem cells inhibits angiogenesis and oxidative stress via FBN1 repression in diabetic retinopathy. Gene Ther, 29:710–719.
110.
LiX, WangY, CaiZ, ZhouQ, LiL, and FuP. (2021). Exosomes from human umbilical cord mesenchymal stem cells inhibit ROS production and cell apoptosis in human articular chondrocytes via the miR-100-5p/NOX4 axis. Cell Biol Int, 45:2096–2106.
111.
LiuHY, YuLF, ZhouTG, WangYD, SunDH, ChenHR, and HouYF. (2020). Lipopolysaccharide-stimulated bone marrow mesenchymal stem cells-derived exosomes inhibit H2O2-induced cardiomyocyte inflammation and oxidative stress via regulating miR-181a-5p/ATF2 axis. Eur Rev Med Pharmacol Sci, 24:10069–10077.
112.
LiuJ, LinM, QiaoF, and ZhangC. (2022). Exosomes derived from lncRNA TCTN2-modified mesenchymal stem cells improve spinal cord injury by miR-329-3p/IGF1R Axis. J Mol Neurosci, 72:482–495.
113.
YeY, LiuQ, LiC, and HeP. (2021). miR-125a-5p regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells under oxidative stress. Biomed Res Int, 2021:6684709.
114.
MaoS, ZhaoJ, ZhangZJ, and ZhaoQ. (2022). MiR-183-5p overexpression in bone mesenchymal stem cell-derived exosomes protects against myocardial ischemia/reperfusion injury by targeting FOXO1. Immunobiology, 227:152204.
115.
ZhangA, BaiZ, YiW, HuZ, and HaoJ. (2021). Overexpression of miR-338-5p in exosomes derived from mesenchymal stromal cells provides neuroprotective effects by the Cnr1/Rap1/Akt pathway after spinal cord injury in rats. Neurosci Lett, 761:136124.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
